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PEndothelial Dysfunction
cute Consumption of Flavanol-Rich Cocoa
nd the Reversal of Endothelial Dysfunction in Smokers
hristian Heiss, MD, PHD,*† Petra Kleinbongard, PHD,† Andrè Dejam, MD, PHD,† Sandra Perré, MS,†
agen Schroeter, PHD,‡ Helmut Sies, MD, PHD,* Malte Kelm, MD†
uesseldorf, Germany; and Davis, California
OBJECTIVES This study was designed to assess the effect of flavanol-rich food on the circulating pool of
bioactive nitric oxide (NO) and endothelial dysfunction in smokers.
BACKGROUND Studies suggest that smoking-related vascular disease is caused by impaired NO synthesis and
that diets rich in flavanols can increase bioactive NO in plasma.
METHODS In smokers (n  11), the effects of flavanol-rich cocoa on circulating NO species in plasma
(RXNO) measured by reductive gas-phase chemiluminescence and endothelial function as
assessed by flow-mediated dilation (FMD) were characterized in a dose-finding study orally
administering cocoa containing 88 to 370 mg flavanols and in a randomized double-blind
crossover study using 100 ml cocoa drink with high (176 to 185 mg) or low (11 mg) flavanol
content on two separate days. In addition to cocoa drink, ascorbic acid and NO-synthase
inhibitor L-NMMA (n  4) were applied.
RESULTS There were significant increases in RXNO (21  3 nmol/l to 29  5 nmol/l) and FMD (4.5
 0.8% to 6.9  0.9%, each p  0.05) at 2 h after ingestion of 176 to 185 mg flavanols, a
dose potentially exerting maximal effects. These changes correlated with increases in flavanol
metabolites. Cocoa-associated increases in RXNO and FMD were reversed by L-NMMA.
Ascorbic acid had no effect.
CONCLUSIONS The circulating pool of bioactive NO and endothelium-dependent vasodilation is acutely
increased in smokers following the oral ingestion of a flavanol-rich cocoa drink. The increase
in circulating NO pool may contribute to beneficial vascular health effects of flavanol-rich
food. (J Am Coll Cardiol 2005;46:1276–83) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.06.055Cardiology Foundation
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digarette smoking leads to atherosclerosis, with the severe
linical end points of myocardial infarction and stroke. Long
efore morphologic alterations of arterial walls become
pparent, an impairment of endothelium-dependent flow-
ediated vasodilation (FMD) can be detected (1). Endo-
helial dysfunction is an early stage of atherosclerosis and
as been attributed to impaired nitric oxide (NO) bioactiv-
ty and enhanced formation of oxygen-derived free radicals
2,3). Endothelium-derived NO is an essential short-lived
ignaling molecule important for vascular homeostasis, in-
luding vasodilation, inhibition of platelet adhesion, and
nhibition of smooth muscle proliferation in the vessel wall
4,5). Until recently, it was supposed that the bioactivity of
O was limited to close temporal and spatial proximity of
he endothelium and that NO could travel only short
istances in the bloodstream before being oxidized to nitrite
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n unrestricted grant and through provision of the cocoa drinks. Drs. Kleinbongard
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orschungsgemeinschaft. Dr. Sies is a Fellow of the National Foundation for Cancer
esearch (Bethesda, Maryland).t
Manuscript received December 1, 2004; revised manuscript received June 3, 2005,
ccepted June 6, 2005.nd nitrate (6). Current studies challenge this concept by
uggesting that NO exists as a pool of various NO-
ontaining plasma components (S- and N-nitrosoproteins,
ron-nitrosyl complexes) (7–9) with bioactivity resembling
hat of authentic NO (10,11); thus, these species together
omprise the circulating NO pool (RXNO). Up to the
resent study, it was unknown whether chronic smoking-
elated impairment of endothelium-dependent vasodilation
easured as FMD extended to the circulating NO pool was
eflected in decreased concentrations of bioactive NO spe-
ies in plasma.
Dietary interventions have suggested that intake of plant-
erived foods and beverages is inversely associated with the
isk of cardiovascular disease (12). These beneficial effects
ave been frequently ascribed to flavanols, a subgroup of
avonoids, the polyphenolic family of antioxidant chemicals
bundantly present in fruits and vegetables (13–15). Studies
n humans and animal models suggested that vascular effects
f flavanols are due, at least in part, to an increased nitric
xide synthase activity and thus an augmented supply of
ioactive NO (16–18). We have recently reported that in
ndividuals with cardiovascular risk factors or coronary
rtery disease, the consumption of a flavanol-rich cocoa
rink can acutely restore endothelium-dependent vasodila-
ion paralleled by an increase in the circulating NO pool
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October 4, 2005:1276–83 Endothelial Dysfunction and Flavanols in Smokers19). The present study is a full report on the subgroup of
mokers from our original study (19). We address the
uestion whether a dietary intervention using a flavanol-rich
ocoa drink can acutely reverse endothelial dysfunction in
mokers and elucidate mechanisms involved.
ETHODS
tudy protocols. In order to assess the potential of dietary
ntervention using flavanol-rich foods to reverse endothelial
ysfunction, plasma RXNO and endothelium-dependent
ilation (FMD) were measured in a subgroup of 11 healthy
olunteers, with smoking as the only major cardiovascular
isk factor (Table 1) (19). Exclusion criteria were hyperten-
ion, diabetes mellitus, hyperlipidemia, malignancies, termi-
al renal failure, and acute inflammation (C-reactive protein
0.5 mg/dl).
To assess the optimal flavanol dose for the larger cross-
ver study (see the following text), a preliminary dose-
nding study was conducted. The RXNO as well as FMD
ere measured in four smokers before and 2 h after (19–22)
ngestion of tap water (100 ml) or 50, 100, and 200 ml of
igh-flavanol cocoa drink (HFCD) (CocoaVia, Mars Inc.,
lough, United Kingdom) on four separate days. The
FCD contained 176 to 185 mg of flavan-3-ols per 100 ml
40% epicatechin/catechin, 60% procyanidins). The vari-
bility of flavanol content was due to several factors,
ncluding natural variations of the flavanol content in
lant-based foods, normal variability produced as a result of
Abbreviations and Acronyms
FMD  flow-mediated dilation
GTN  glycerol trinitrate
HFCD  high-flavanol cocoa drink
LFCD  low-flavanol cocoa drink
NOS  nitric oxide synthase
RXNO  sum of circulating NO species
able 1. Characteristics of Study Population
Smokers
11
ge, yrs 31  1
ender, M/F 6/5
MI, kg/m2 21.8  0.8
ean arterial pressure, mm Hg 87  2
otal cholesterol, mg/dl 192  5
DL, mg/dl 116  5
DL, mg/dl 67  6
lucose, mg/dl 86  1
ack-years 12  2
igarettes per day 17  2
XNO, nmol/l 21  3
rachial artery diameter, mm 4.2  0.2
low-mediated dilation, % 4.5  0.8
lycerol trinitrate-mediated dilation, % 14.7  2.1
ata given as mean  SE.a
BMI  body mass index; HDL  high-density lipoprotein; LDL  low-density
ipoprotein; RXNO  sum of circulating species.ommercial-scale food manufacturing, and the variability of
he analytic methods employed. Selected flavanol metabo-
ites were estimated from plasma samples.
On the basis of the results of our dose-finding study, we
esigned a larger randomized double-blind crossover study
19). On two days, RXNO and FMD were measured before
nd 2 h after double-blind ingestion of 100 ml HFCD or
ontrol low-flavanol cocoa drink (LFCD) (100 ml cocoa
rink with 11 mg of flavanols [CocoaVia, Mars Inc.]). In
ur original study (19), we used a balanced crossover design
ith 10 individuals receiving flavanol-rich drinks on their
rst study day and 10 on the second day. Six of each group
ere included in the subgroup of smokers (n  12 total).
ne female subject (HFCD on day 1) was excluded because
f hypercholesterolemia after completion of the study,
esulting in 11 smokers (n 5 HFCD and n 6 LFCD on
ay 1). Both drinks were similar in taste and indistinguish-
ble by color and packaging; furthermore, these products
ere matched on the basis of macronutrients, calories,
heobromine, and caffeine (Table 2).
To gain more insight into the potential mechanisms
nderlying the observed vascular responses, HFCD was
dministered to a randomly chosen subset of the 11 smokers
escribed earlier on two separate days (n 4). After the 2-h
ime point, nitric oxide synthase (NOS) was inhibited by
ntravenous infusion of L-NG-monomethyl-arginine (L-
MMA) (Clinalfa, Laeufelfingen, Switzerland) over 30
in and measurements were repeated. Infusion rates were 1
g·kg·1·min1 for the first 3 min followed by 0.2
g·kg·1·min1 for 27 min sufficient to abolish NO-
ependent FMD in healthy nonsmoking volunteers (data
ot shown). Ascorbic acid was reported to increase NO
ynthesis in smokers (23). To elucidate whether ascorbic
cid further increases FMD and RXNO, a group of smokers
n 4) received 2 g intravenous L-ascorbic acid (20 ml 0.57
ol/l; Cebion N forte, Merck, Darmstadt, Germany) in
ddition to the HFCD (administered at 0 h) at the 2-h time
oint.
Volunteers fasted overnight and were required to refrain
rom smoking 12 h before beginning and during the entire
able 2. Composition of Cocoa Drinks
Per 100 ml High Flavanol Control
otal flavanols, mg 176–185 11.5
Monomers, mg 70–74 1
Epicatechin, mg 20–22 1
Procyanidins, mg 106–111 11.4
affeine, mg 8.6 4.3
heobromine, mg 128.9 125.8
nergy, kJ (kcal) 307 (73) 277 (66)
otal protein, g 3 3.1
otal carbohydrate, g 13.2 12.1
Dietary fibers, g 0.87 0.24
Sugars, g 12.4 11.8
otal fat, g 0.89 0.57ssessment period. The study was performed at the Heinrich-
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Endothelial Dysfunction and Flavanols in Smokers October 4, 2005:1276–83eine University, Duesseldorf, Germany, after formal ap-
roval of the protocol by the local ethics committee.
easurement of vascular parameters. Flow-mediated di-
ation was measured as previously described (24,25). Briefly,
he diameter of the brachial artery was measured by a 15
Hz transducer (Sonos 5500, Philips Medizin Systeme,
amburg, Germany) and automatic edge-detection soft-
are (Brachial Analyzer, Medical Imaging Applications,
owa City, Iowa) yielding a coefficient of variation of 1%.
eactive hyperemia was induced by 5 min of distal lower
rm occlusion. After 60 s, the diameter was assessed and
MD calculated as relative diameter gain compared to
aseline. In our laboratory, reference values are 7.1  0.6%
n a comparable nonsmoking control group without
ypertension, diabetes, or hypercholesterolemia (26).
ndothelium-independent dilation was measured 4 min
fter sublingual application of 400 g glycerol trinitrate.
ean arterial pressure was calculated as 1/3 (systolic-
iastolic blood pressure) plus diastolic blood pressure.
iochemical parameters. Plasma levels of circulating NO
ool (RXNO: sum of S-, N-nitrosothiols, and iron-nitrosyl
omplexes) were determined using a gas-phase chemilumines-
ence assay (27). Using the identical methodology, we have
easured 36  2 nmol/l plasma RXNO in a comparable
onsmoking control group without hypertension, diabetes, or
ypercholesterolemia. Whole blood was diluted 1:5 in ice-cold
.9% saline containing N-ethylmaleimide (5 mmol/l) and
DTA (2 mmol/l) and centrifuged at 750  g for 5 min.
lasma was treated with 1/10 volume of 5% sulfanilamide in
M HCl for 10 min and then injected into a tri-iodide–
ontaining vessel actively purged with a helium stream in line
ith an NO chemiluminescence analyzer (88NOe, EcoPhys-
cs, Duernten, Switzerland). Flavanol (epicatechin and cate-
hin) and select flavanol metabolites (epicatechin-7-beta-
-glucuronide, 4=-O-methyl-epicatechin, 4=-O-methyl-
picatechin--D-glucuronide) present in plasma were
nalyzed by an HPLC with an FLD detection system
Hewlett Packard 1100 Series, Mississauga, Ontario, Canada);
PLC column: Phenomenex C18(2) 150  4.8 mm, 3 m)
nder utilization of authentic standards as detailed elsewhere
28,29).
tatistical analyses. Results are expressed as means  SE.
omparisons between groups were analyzed by Student t
est. Repeated measurements two-way analysis of variance
as used to estimate intra-individual effects. Pairwise com-
arisons were corrected by the Bonferroni confidence inter-
al. Correlations were determined with two-tailed Pearson’s
value. Normal distribution was estimated using
olmogorov-Smirnov test. Statistical significance was as-
umed if a null hypothesis could be rejected at p  0.05.
ncreases in RXNO, FMD, and flavanol metabolites were
alculated as data at given time points minus baseline. All
nalyses were performed with SPSS 11.0.1 (SPSS Inc,
hicago, Illinois).
s
mESULTS
aseline characteristics of study population. The clinical
aseline characteristics (age, gender, body mass index, mean
rterial pressure, total cholesterol, low-density lipoprotein
nd high-density lipoprotein cholesterol, and fasting plasma
lucose) were within normal limits (Table 1). Smokers had
history of 12 2 pack-years and smoked 17 2 cigarettes
er day as assessed by the reported number of cigarettes
moked on the day before the first study day. The baseline
lasma concentration of RXNO was 21  3 nmol/l and
MD was 4.5  0.8%. No significant correlations between
aseline smoking behavior (pack years, cigarettes per day)
nd FMD or plasma RXNO at baseline were seen.
ose-dependence of flavanols on circulating NO pool in
mokers. In order to assess optimal flavanol dose to be used
n a larger crossover study, increasing volumes of HFCD
ere administered. Dose-dependent increases in RXNO
50 ml [88 to 92 mg total flavanols]: 13  1 nmol/l to 17 
nmol/l, p  0.023; 100 ml [176 to 185 mg]: 14  1
mol/l to 23  1 nmol/l, p  0.001; 200 ml [352 to 370
g]: 13 1 nmol/l to 23 1 nmol/l, p 0.001) and FMD
50 ml: 3.3  0.8% to 4.1  0.6%, p  0.444; 100 ml: 2.2
1.0% to 5.9  0.6%, p  0.030; 200 ml: 3.8  1.2% to
.5  0.8%, p  0.039) were observed 2 h after consump-
ion of HFCD (p values corrected for three pairwise
omparisons). Figure 1 depicts absolute increases in RXNO
nd FMD over baseline. Neither ingestion of 100 ml tap
ater nor LFCD (11 mg) had a significant effect on
igure 1. Dose-finding. Flavanol-rich cocoa dose-dependently increased
he circulating nitric oxide (NO) pool (RXNO) (A) and flow-mediated
ilation (FMD) (B) at 2 h (filled circles). RXNO and FMD did not
ignificantly change after water control (C, open circles). Data represent
eans  SE. (n  4 smokers) *p  0.05.
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October 4, 2005:1276–83 Endothelial Dysfunction and Flavanols in SmokersXNO and FMD (data not shown). As there were no
ignificant differences between the effects on RXNO and
MD observed after the consumption of 100 or 200 ml, the
00 ml dosage was used in the crossover trial (30).
Plasma levels of free aglyconic flavanols, as well as those
f conjugated flavanol metabolites, which represent only a
elected subset of those present in plasma, increased signif-
cantly only following the ingestion of 100 ml HFCD
ontaining 176 mg of total flavanols. However, following
asal level corrections, the ingestion of 50 ml HFCD (88 to
2 mg total flavanols) was without effect. (Table 3) The
ncreases in epicatechin (r 0.75, p 0.005), catechin (r
.76, p  0.004), epicatechin-7-beta-D-glucuronide (r 
.69, p  0.013), 4=-O-methyl-epicatechin (r  0.65, p 
.022), and 4=-O-methyl-epicatechin--D-glucuronide (r
0.67, p 0.018) correlated significantly with the increase
n RXNO. The increases in FMD correlated with the
ncrease in epicatechin (r  0.66, p  0.020) and catechin
r  0.62, p  0.031)
Flavanol-rich cocoa drink acutely increased RXNO and
eversed endothelial dysfunction. On the basis of the dose-
nding data (Fig. 1), we performed a randomized double-
lind crossover study using a cocoa drink high in flavanols
HFCD) and the matched low-flavanol cocoa beverage
LFCD) (Table 2). We performed a repeated-
easurements analysis of variance with two within-subject
actors (baseline vs. 2 h post-drink and high-flavanol drink
s. control drink) and found a significant two-way interac-
ion (FMD, p  0.002; RXNO, p  0.03). The pairwise
omparison showed that RXNO and FMD significantly
ncreased 2 h after ingestion of 100 ml HFCD (4.2  0.9%
o 6.9  0.9%, p  0.001, and 20  3 nmol/l to 29  2
mol/l; p  0.001) (Figs. 2A and 2B), but was unaltered
fter the LFCD (4.5 0.9% to 3.6 0.9%, p 0.141, and
3  4 nmol/l to 20  3 nmol/l, p  0.452) (Figs. 2C and
D) (each p corrected for two comparisons), and baseline
alues were not significantly different on the two study days.
nterestingly, we found strong correlations between the
umber of cigarettes smoked per day and the absolute
ncreases in plasma RXNO (r 0.73, p 0.011) and FMD
r  0.69, p  0.020) 2 h following the ingestion of the
igh-flavanol drink. There were no significant correlations
etween the pack-years and the increases in RXNO (r 
able 3. Plasma Flavanol Metabolites at Baseline and Following
88–92
Baseline
picatechin, nmol/l 3  0
atechin, nmol/l 10  2
picatechin-7--D-glucuronide, nmol/l 11  7
=-O-methyl-epicatechin, nmol/l 22  8
=-O-methyl-epicatechin--D-glucuronide, nmol/l 157  31
p  0.05 (baseline vs. 2 h)..40, p  0.218) or FMD (r  0.50, p  0.120).
s
vOS dependence of flavanols effects. In order to gain
echanistic insight, we inhibited NOS or alternatively
dministered ascorbic acid on top of the observed effects.
itric oxide synthase inhibition via L-NMMA, mimicking
cute endothelial dysfunction, abolished cocoa-related im-
rovement of endothelial dysfunction and increase in the
irculating NO pool. (Figs. 3A and 3B). Ascorbic acid has
een shown to increase endothelial function in smokers by
ncreasing tetrahydrobiopterine, a cofactor of NOS (23).
ere, we observed no further increase of improvement in
fter Consumption of Cocoa Beverage
Flavanol Content of Drinks, mg
176–185 352–370
h Baseline 2 h Baseline 2 h
 0 3  0 11  3* 6  3 19  6*
 3 7  2 19  7 8  2 18  3*
 3 9  6 38  19 14  4 39  13*
 5 23  9 38  12 26  9 41  10*
 46 156  32 202  40* 184  59 287  58*
igure 2. Restoration of circulating nitric oxide (NO) pool by flavanol-rich
ocoa drink. Randomized double-blind crossover design, ingestion of 100
l flavanol-rich cocoa drink (176 to 185 mg flavanols) increased (A)
irculating NO pool (plasma RXNO) and (B) flow-mediated dilation after
h (n  11 smokers). Ingestion of the matched control drink had no2 h A
2
3
9
9
25
151ignificant effect on both parameters (C, D). Filled circles  individual
alues; open circles  means  SE. *p  0.05.
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Endothelial Dysfunction and Flavanols in Smokers October 4, 2005:1276–83ndothelial dysfunction and circulating NO pool after
pplication of ascorbic acid in a dose sufficient to reverse
ndothelial dysfunction in smokers when applied alone
Figs. 3C and 3D).
ISCUSSION
he circulating NO pool and flow-mediated dilation were
cutely increased following the consumption of a flavanol-
ich cocoa beverage. The increases in RXNO and endothe-
ial function were NOS-dependent, as NOS inhibition
bolished the observed effects. Ascorbic acid did not further
ncrease both parameters, suggesting a parallel antioxidant
echanism. The increase in individual flavanol metabolites
orrelated with the increase in NO.
The RXNOs exhibit biologic vasoprotective actions sim-
lar to NO in vivo as well as in vitro (31), including
asodilation (11,27), inhibition of platelet aggregation (32),
nd interruption of carotid embolization (33). In fact,
tudies imply that RXNOs in plasma represent a physiologic
torage pool for bioactive NO in human blood capable of
ompensating for local NO deficit. Cannon et al. (10) have
hown that inhaled NO can restore blood flow and vascular
igure 3. Effects of L-NMMA and vitamin C on cocoa effects. Both flow
RXNO) (B and D) increased 2 h after ingestion of cocoa containing 176 t
elow baseline values, ascorbic acid (2 g, C and D) did not cause a further i
orrected for 8 pairwise comparisons in RXNO and FMD. Columns represistance in the forearm during regional inhibition of NO dynthesis. Results from our group suggest that plasma
XNO contributes to systemic vasodilator effects of NO
fter intravenous and intra-arterial infusion (11).
Endothelial function as measured by FMD is commonly
sed as a clinical readout of endothelial NO synthesis
1,34). Flow-mediated dilation of the brachial artery is
lmost entirely NOS-dependent (34) and correlates very
ell with endothelial function of most other conduit arter-
es, including the coronary arteries, and can therefore be
sed as a surrogate for systemic NO synthesis. Several
roups have previously shown that smokers show an im-
aired FMD with normal vasodilation in response to oral
lycerol trinitrate (1,35). The baseline values for FMD and
lasma RXNO measured in smokers were significantly
ower than values we have previously measured in healthy
on-smokers (27). Thus, a decreased pool of circulating NO
n smokers may be secondary to decreased endothelial
unction and may potentially contribute to chronic vascular
isease.
We show in smokers 12 h after smoking cessation and
uring abstinence from smoking that the consumption of a
avanol-rich, but not a flavanol-poor, beverage dose-
iated dilation (FMD) (A and C) and the circulating NO pool in plasma
mg of flavanols. Whereas L-NMMA (A and B) reversed both parameters
e when given after measurements at the 2-h time point. Significance levels
means  SE (n  4 smokers).-med
o 185ependently increased the circulating NO pool in plasma
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October 4, 2005:1276–83 Endothelial Dysfunction and Flavanols in Smokersnd FMD response by approximately 50% These findings
re novel as they were obtained from a study population for
hich smoking represented the only cardiovascular risk
actor. Thus, our findings further support previous epide-
iologic investigations and dietary interventions in humans
hat demonstrated a beneficial role for cocoa flavanols in the
eneral context of cardiovascular health (19,36–38). An
ncreased circulating NO pool may in part compensate for
egional deficits, for example, potentially inhibiting
latelet adhesion to arteriosclerotic plaques, stabilizing
laques by inhibition of low-density lipoprotein oxida-
ion, and dilating stenosed conduit vessels. Mechanisti-
ally, it is interesting to note that the magnitude of
ncrease in RXNO and FMD correlated with the number
f cigarettes smoked, but not with the baseline levels of
oth parameters or the pack-years. This suggests that
art of the effect may be due to reversal of acute cigarette
moke-related effects.
We observed that a flavanol-related improvement of
XNO and endothelial function can be reversed by
-NMMA infusion, but not further increased by ascorbic
cid. Given the reversal of effects following NOS inhibition,
t can be argued that the mechanism of action of flavanol-
ich food involves an increase in NOS activity. This is
urther supported by Fisher et al. (17), who investigated the
nfluence of flavanol-rich cocoa and NO synthase inhibition
n blood flow in the finger of otherwise normal healthy
ubjects. Potential mechanisms leading to acutely increased
OS activity following ingestion of flavanol-rich foods may
nvolve antioxidant properties of flavanols similar to ascorbic
cid, either sparing NO from degradation or increasing NO
ynthesis. Whether one or the other of these potential
echanisms is responsible for the observed effects in this
tudy, or indeed a combination of both, cannot be con-
luded from the present data because both mechanisms are
ependent on each other. Data from investigations in vitro
nd in vivo demonstrated previously that various factors
ssociated with oxidative stress, including smoking (1),
nflammation (39), vitamin deficiency, and others resulted
n a decline of NO production and in decreased levels of
etrahydrobiopterin (BH4), an essential cofactor of NOS.
oncordantly, free radicals present in cigarette smoke and
ncreased endogenous radical generation secondary to ciga-
ette smoking (2) were suggested to uncouple NOS by
ausing a decrease in BH4, subsequently leading to lower
OS and release (40). In this context, ascorbic acid admin-
stration has been shown in vivo (41) and in vitro (42) to
ttenuate the oxidative stress-related abrogation of NO
roduction by either replenishing BH4 or by preventing its
oss through mechanisms that are causally linked to the
ntioxidant properties of ascorbic acid. Although ascorbic
cid has been shown previously to increase the FMD
esponse in smokers (23,41), the injection of ascorbic acid in
he context of flavanol-rich cocoa ingestion did not result in
dditional increases in FMD as compared with flavanol-rich
ocoa alone. The lack of such additive effects implies either Hhat flavanol-rich cocoa consumption resulted in a satura-
ion of ascorbate-mimicking antioxidant effects or that
ocoa consumption resulted in a maximal FMD response
hat is seemingly independent of antioxidant mechanisms as
licited by ascorbate.
Regarding the identification of the bioactive flavanol/
etabolite(s), it has to be noted that flavanols are subject to
xtensive phase I/II metabolism in gut and liver (20,43,44).
hey also undergo a variety of biotransformations that are
elated to the activity of enzymes inherent to the gut
icroflora (45). Thus, the flavanol metabolites present in
irculation represent a variety of primary, structurally related
s well as secondary metabolites, which exhibit various
ifferences in their physical and chemical properties as
ompared with the native flavanols ingested. Although
arious investigators have previously reported on general
spects of flavanol metabolism following the ingestion of
ertain fruit, wine, tea, and cocoa products, information on
avonoid metabolites in the context of specific pathology-
elated dietary interventions is scarce. Most investigators use
n enzyme hydrolysis to cleave glucuronides and sulphates
o aglycones and O-methylated flavanol derivatives before
nalyzing plasma or urinary samples. Although this ap-
roach does provide the required evidence that flavanols
ere absorbed, and thus were present in circulation, any
nformation regarding the identity of specific metabolites,
hich may be essential in determining the active flavanol
erivatives, will be lost. Thus, during this investigation, we
ave aimed at providing not just evidence of flavanol
bsorption, but also information regarding the identity of
redominant circulating flavanol metabolites. The correla-
ion between increases in RXNO, FMD, and increases in
he selected flavanol metabolites in plasma suggests that
he observed effects are indeed related to ingested fla-
anols. Furthermore, the results obtained demonstrate
hat 4=-O-methyl-epicatechin--D-glucuronide is likely
ne of the major metabolites present in circulation
ollowing the ingestion of the cocoa beverage used,
eaching maximal plasma concentration of up to 287
mol/l. However, baseline values are relatively high, and
t is also possible that there are other major metabolites in
lasma that may be responsible for the observed effects,
r that flavanols are only indicators of unknown bioactive
ubstances in cocoa.
onclusions. Taken together, the results herein suggest
hat the circulating pool of bioactive NO and endothelium-
ependent dilation are acutely increased by intake of a
avanol-rich cocoa drink during abstinence from smoking.
his supports the concept that dietary flavanols can reverse
ndothelial dysfunction. The increase in circulating NO
pecies may contribute to the potential health effects of
avanol-rich foods and may have application for the treat-
ent of diseases characterized by impaired regional NO
roduction, such as peripheral and coronary artery disease.
owever, long-term studies are needed to investigate
w
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nto long-term health benefits.
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